APA (7th ed.) Citation

Davis, K., Valente Pinto, M., Andrews, N. J., Goldblatt, D., Borrow, R., Findlow, H., . . . Snape, M. D. (2021). Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): Outcomes of a multicentre, open-label, randomised controlled trial. Lancet Infectious Diseases, 21(5), 688. https://doi.org/10.1016/S1473-3099(20)30600-9

Chicago Style (17th ed.) Citation

Davis, Kimberly, et al. "Immunogenicity of the UK Group B Meningococcal Vaccine (4CMenB) Schedule Against Groups B and C Meningococcal Strains (Sched3): Outcomes of a Multicentre, Open-label, Randomised Controlled Trial." Lancet Infectious Diseases 21, no. 5 (2021): 688. https://doi.org/10.1016/S1473-3099(20)30600-9.

MLA (9th ed.) Citation

Davis, Kimberly, et al. "Immunogenicity of the UK Group B Meningococcal Vaccine (4CMenB) Schedule Against Groups B and C Meningococcal Strains (Sched3): Outcomes of a Multicentre, Open-label, Randomised Controlled Trial." Lancet Infectious Diseases, vol. 21, no. 5, 2021, p. 688, https://doi.org/10.1016/S1473-3099(20)30600-9.